Envisioning how to advance the MASH field

• Published in: Nature reviews. Gastroenterology & hepatology 2024-10, Vol.21 (10), p.726-738
• Main Authors: Allen, Alina M., Younossi, Zobair M., Diehl, Anna Mae, Charlton, Michael R., Lazarus, Jeffrey V.
• Format: Article
• Language: English
• Subjects: 692/4020/4021/1607/2750; 692/4020/4021/1607/2751; 692/699/317; 692/700/478; Biomedicine; Fatty liver; Gastroenterology; Hepatology; Humans; Liver cancer; Liver diseases; Medicine; Medicine & Public Health; Metabolism; Nomenclature; Non-alcoholic Fatty Liver Disease - therapy; Perspective; Public health
• ISSN: 1759-5045; 1759-5053; 1759-5053
• DOI: 10.1038/s41575-024-00938-9

Since 1980, the cumulative effort of scientists and health-care stakeholders has advanced the prerequisites to address metabolic dysfunction-associated steatotic liver disease (MASLD), a prevalent chronic non-communicable liver disease. This effort has led to, among others, the approval of the first drug specific for metabolic dysfunction-associated steatohepatitis (MASH; formerly known as nonalcoholic steatohepatitis). Despite substantial progress, MASLD is still a leading cause of advanced chronic liver disease, including primary liver cancer. This Perspective contextualizes the nomenclature change from nonalcoholic fatty liver disease to MASLD and proposes important considerations to accelerate further progress in the field, optimize patient-centric multidisciplinary care pathways, advance pharmacological, behavioural and diagnostic research, and address health disparities. Key regulatory and other steps necessary to optimize the approval and access to upcoming additional pharmacological therapeutic agents for MASH are also outlined. We conclude by calling for increased education and awareness, enhanced health system preparedness, and concerted action by policy-makers to further the public health and policy agenda to achieve at least parity with other non-communicable diseases and to aid in growing the community of practice to reduce the human and economic burden and end the public health threat of MASLD and MASH by 2030. This Perspective discusses the nomenclature change from nonalcoholic fatty liver disease to metabolic dysfunction-associated steatotic liver disease (MASLD) and proposes steps necessary to improve care and end the public health threat posed by MASLD and metabolic dysfunction-associated steatohepatitis.